

AMENDMENTS TO THE CLAIMS:

1-12. (canceled)

13. (currently amended) A pteridine derivative selected from the group consisting of:

- 2-amino-4-morpholino-6-(4-acetanilide) pteridine,
- 2-amino-4-morpholino-6-(3-acetanilide) pteridine,
- 2-amino-4-morpholino-6-(4-aminophenyl) pteridine,
- 2-amino-4-morpholino-6-(3-aminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-benzoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-propionylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-furoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-cyclohexanoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-[4-(4-chlorobenzoyl)aminophenyl] pteridine,
- 2-amino-4-morpholino-6-(4-benzyloxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-isonicotinoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(4-naphtoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(4-methylsulfonylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(4-ethylsuccinylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-[4-(4-methylbenzoate)aminophenyl] pteridine;
- 2-amino-4-morpholino-6-(3-benzoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-benzensulfonylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(3-phenoxyacetylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-isonicotinoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-cyclohexanoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-[3-(4-methylbenzoate)aminophenyl] pteridine;
- 2-amino-4-morpholino-6-(3-ethylsuccinylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-ethylmalonylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-benzyloxyacetylaminophenyl) pteridine,

- 2-amino-4-morpholino-6-(3-ethylsulfonylaminophenyl)pteridine,
- 2-amino-4-morpholino-6-[3-Boc-(L)-phenylalanine-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(D)-phenylalanine-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(L)-tryptophane-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(D)-tryptophane-aminophenyl] pteridine, and
- 2-amino-4-morpholino-6-(4-hydroxyphenyl) pteridine,
- 2,4-di-(thienyl-2-methylamino)-6-(3,4-dimethoxy-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-ethoxyphenyl) pteridine,
- 2-amino-4-morpholino-6-(4-benzyloxyphenyl) pteridine,
- 2-amino-4-morpholino-6-(4-(phenethyloxy)-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxy-butyronitrile) pteridine,
- 2-amino-4-morpholino-6-(4-propoxy-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxy-butyric acid ethyl ester) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxy-acetic acid ethyl ester) pteridine,
- 2-amino-4-morpholino-6-(4-(2-methoxyethoxy)-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-butoxy-phenyl)-pteridine,
- 2-amino-4-(diethanolamino)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-(benzylamino)-6-[[3,4-(dimethoxyphenyl)]pteridine;
- 2-amino-4-(phenylethylamino)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-(4-methyl-piperidine)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-(2-thienylmethylamino)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-thiomorpholine-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-((R)-sec-butylamine)-6-[[3,4-(dimethoxyphenyl)]pteridine, and
- 2-amino-4-((S)-sec-butylamine)-6-[[3,4-(dimethoxyphenyl)]pteridine.

14. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13.

15. (currently amended) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13, and further comprising one or more biologically active drugs selected from the group consisting of immunosuppressant and/or immunomodulator drugs, ~~antihistamines, antineoplastic drugs and anti-allergic drugs.~~

16. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13, and further comprising one or more immunosuppressant drugs selected from the group consisting of cyclosporin A; pentoxifylline; daltroban, sirolimus, tacrolimus; rapamycin; leflunomide; mycophenolic acid and salts thereof; azathioprine, brequinar; gusperimus; 6-mercaptopurine; mizoribine; chloroquine; hydroxy-chloroquine; etanercept; infliximab; and kineret.

17. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more immunomodulator drugs selected from the group consisting of acemannan, amiprilose, bucillamine, ditiocarb sodium, imiquimod, Inosine Pranobex, interferon- β , interferon- γ , lentinan, levamisole, pidotimod, romurtide, platonin, procodazole, propagermanium, thymomodulin, thymopentin and ubenimex.

18. (canceled)

19. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more pharmaceutically acceptable carriers or excipients.

20. (currently amended) A method of prevention or treatment of a pathologic condition selected from the group consisting of ankylosing spondylitis, Sjögren syndrome and asthma, ~~immune and auto-immune disorders, cardiovascular disorders, disorders of the central nervous system, cell proliferative disorders and allergic conditions,~~ said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13.

21. -27. (canceled)